Background and Purpose-Chinese patients largely experience acute ischemic stroke (AIS) because of large artery atherosclerosis rather than cardioembolism, and whether tirofiban is safe and effective in these patients treated with endovascular thrombectomy (ET) is unknown. This study evaluated the safety and efficacy of tirofiban in Chinese patients with AIS treated with ET. Methods-This observational study is based on a single-center prospective registry study. Patients with AIS undergoing ET with second-generation stent retrievers from January 2013 to February 2017 were treated with ET alone or ET plus low dose of tirofiban. The primary outcome was symptomatic intracerebral hemorrhage (sICH). The secondary outcomes included rate of early reocclusion, any ICH, fatal ICH, and 3-month and long-term functional outcomes. Results-One hundred eighty AIS subjects were included in the analysis, including 90 subjects treated with tirofiban and 90 subjects without tirofiban. Sixty-three subjects (35%) had any ICH, 19 of them (11%) were sICH, and 9 of them (5%) were fatal ICH. Ten subjects (11%) treated with tirofiban experienced sICH and 9 subjects (10%) not given tirofiban experienced sICH, not a significant difference (P=0.808). Early reocclusion happened in 4 of 90 subjects (4.4%) treated with tirofiban and 8 of 90 subjects (8.9%) not treated with tirofiban (P=0.370). One hundred sixty-one subjects (89%) completed long-term follow-up, subjects treated tirofiban were associated with lower odds of death (23% versus 44%, P=0.005) when compared with those who were not treated. Additionally, tirofiban was associated with better odds of long-term functional independence (adjusted odds ratio, 4.37; 95% confidence interval, 1.13-16.97; P=0.033). Conclusions-In patients with AIS undergoing ET, tirofiban is not associated with higher sICH, it seems to lead to lower odds of deaths and better odds of long-term functional independence. Further investigations are needed to determine the efficacy of tirofiban in preventing early reocclusion, the underlying mechanisms, and its optimal treatment protocol. (Stroke.
S econd-generation stent-retriever devices have been demonstrated to be able to revascularize occluded intracranial arteries and improve functional outcomes of patients with acute ischemic stroke (AIS).
1,2 However, endothelial injuries may be an inevitable complication and that may lead to early reocclusion. 3, 4 Tirofiban, a glycoprotein IIb/IIIa antagonist with a short half-life, therefore is used in some centers to prevent local platelet aggregation and early reocclusion. 5, 6 It has been demonstrated to be safe in acute moderate ischemic stroke patients with a reduced mortality after 5 months. 7 In AIS patients treated with full dose intravenous alteplase, immediate bridging therapy with intravenous tirofiban is also safe and feasible. 8 However, a previous study showed that tirofiban was associated with poor outcome and increased the risk of fatal intracerebral hemorrhage (ICH) in AIS patients treated with endovascular thrombectomy (ET). 9 In Asian countries like China, intracranial atherosclerotic disease is more common than in Western countries. 10, 11 The pathogenesis of the stroke in many Chinese patients with AIS is large artery atherosclerosis, 12 and approximately half of
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them have intracranial artery stenosis. 10 It may be much difficult to achieve good reperfusion with stent retrievers alone in these patients, 5 therefore permanent stenting or balloon angioplasty is often used to achieve sufficient recanalization. 13, 14 Tirofiban is commonly used to prevent early reocclusion after ET. 5, 6 However, whether tirofiban is safe and effective in these patients treated with ET is unclear.
In this study, we aimed to evaluate the safety of low-dose tirofiban in AIS patient treated with ET, and investigate whether it can prevent early reocclusion and improve functional outcome.
Methods
Data Availability
The data, analytic methods, and study materials of this study are available from the corresponding author on reasonable request.
The study population, including the inclusion and exclusion criteria, and data collection are described in the online-only Data Supplement.
Interventions
According to the local catheter laboratory regulations, interventionists, who has been practicing interventional neuroradiology for >5 years and able to perform extracranial and intracranial stents proficiently, were qualified to perform endovascular treatment for patients with AIS after systematic training. Local or general anesthesia was chosen according to the level of patient cooperation and the medical condition of the patient. All procedures were performed via a transfemoral approach. Intravenous heparin to maintain the activated clotting time ranged 250 to 300 s during the procedure was mandatory, except subjects treated with intravenous alteplase. The type and size of stent retriever, other necessary devices (eg, guide wires and catheters), and strategies of intervention were left to the discretion of the interventionists.
The use of tirofiban or not was at the interventionists' discretion according to the characteristics of the occlusion and the situation of the procedure (Methods in the online-only Data Supplement). If used, a low-dose bolus of Tirofiban Hydrochloride and Sodium Chloride Injection (Grand Pharmaceutical Co Ltd, China; Standard: 5 mg of tirofiban diluted with 100 mL of normal saline) was administrated intra-arterially (standardly, at a rate of 1 mL/min; the dose ranged from 0.25-0.5 mg). Intravenous tirofiban was continued at a rate of 4 to 5 mL/h (ie, 0.2-0.25 mg/h) for 12 to 24 hours and bridged with dual antiplatelet if the follow-up computed tomography (CT) found no obvious ICH. Dual antiplatelet and intravenous tirofiban overlapped for 4 hours, and then intravenous tirofiban was stopped. If tirofiban was not used, the treating interventionists would determine whether the subjects were treated with dual antiplatelet management immediately or several hours after the procedures. Dual antiplatelets with 100 mg Aspirin and 75 mg Clopidogrel were used once daily. However, for patients naive to antiplatelet prestroke, loading dose of 300 mg Aspirin plus 300 mg Clopidogrel was chosen. For patients on Aspirin only prestroke, a loading dose of 300 mg Clopidogrel plus 100 mg Aspirin was used; and for patients who used Clopidogrel alone prestroke, a loading dose of 300 mg Aspirin plus 75 mg Clopidogrel was used.
End Points
The primary outcome was symptomatic ICH (sICH). sICH was defined according to the definition of the ECASS-III study (European Cooperative Acute Stroke Study III; any apparently extravascular blood in the brain or within the cranium that was associated with clinical deterioration, as defined by an increase of 4 points or more in the score on the National Institutes of Health Stroke Scale (NIHSS), or that led to death, was identified as the predominant cause of the neurological deterioration). 15 The secondary outcomes were (1) early reocclusion of the recanalized arteries, (2) any ICH according to the definition of the Heidelberg Bleeding Classification, 16 (3) fatal ICH, (4) functional outcomes at 3-month follow-up, and (5) functional outcomes of longterm follow-up. Long-term follow-up was defined as follow-up after 3 months, which were ascertained by telephone interviews or clinic visits (which came later). Reocclusion was defined as initial complete or partial recanalized arteries with occlusion recurring at the same site as assessed by post-treatment transcranial color Doppler or in combination with CT angiography (if available). Functional outcome was assessed by modified Rankin Scale (mRS), with mRS scores of 0 to 1 indicates no disability, mRS scores of 0 to 2 indicates functional independence, and mRS score of 6 indicates death.
Imaging Evaluation
Head CT was generally performed 12 to 24 hours and 72±6 hours post-treatment respectively or whenever an ICH was indicated by clinical evidences. All imaging, including angiograms, pre-and post-treatment CT, and post-treatment magnetic resonance imaging (if available), were separately analyzed by a neurologist and a neuroradiologist who were masked to the subjects' treatment protocol and clinical outcomes. Alberta Stroke Program Early Computed Tomography Score (ASPECTS) and posterior circulation ASPECTS (pc-ASPECTS) were evaluated on pretreatment CT for subjects with anterior circulation stroke (ACS) and posterior circulation stroke (PCS) respectively. 17, 18 ICH was assessed on the post-treatment CT. Disagreements were resolved by reaching a consensus between the 2 readers, or, if no consensus could be reached, a third reader had the final decision.
Statistical Methods
Baseline characteristics and operational details were compared between subjects treated with tirofiban and without tirofiban. Any ICH, sICH, fatal ICH, and 3-month and long-term functional outcome were also compared between subjects treated with tirofiban and without tirofiban. Subjects of ACS and PCS were analyzed respectively. Multivariate analysis was performed with any ICH, sICH, or fatal ICH as the dependent variable and with previous stroke, diabetes mellitus, age, baseline NIHSS, pretreatment with antiplatelet or anticoagulation, atrial fibrillation, ASPECTS/pc-ASPECTS, treatment with additional intra-arterial thrombolysis, and treatment with intravenous alteplase and tirofiban as the covariates. In addition, multivariate analysis was also performed with functional outcome as the dependent variable and with previous stroke, diabetes mellitus, age, baseline NIHSS, pathogenesis of stroke, ASPECTS/pc-ASPECTS, location of stroke (ACS or PCS), thrombolysis in cerebral infarction (TICI) scores, and tirofiban as the covariates.
For continuous data, mean±SD or medians (interquartile range, IQR) were used to summarize data, and 2-sided t test for independent samples or Mann-Whitney U Tests was performed to detect differences between groups. For binary data, frequencies and % were used to summarize data, and between-group comparisons were performed via the χ 2 or Fisher exact tests when appropriate. All data were analyzed using SPSS 19.0 (IBM Inc) with the significance level of P<0.05 (2 sides).
Results
From January 2013 to February 2017, a total of 180 consecutive AIS subjects with proximal large artery occlusion were treated with ET by using second-generation stent retrievers, including 118 with ACS and 62 with PCS.
Demographic and Clinical Characteristics
The baseline characteristics of all 180 subjects are summarized in Table 1 . The average age at onset was 61.3±12.8 years old, 129 subjects (72%) were male, and 42 subjects (23%) were treated with intravenous alteplase (Table 1 ). The median baseline NIHSS score was 20 (IQR, 14-30), the median baseline ASPECTS/pc-ASPECTS was 9 (IQR, 8-10), the median times from onset to groin puncture and recanalization were 312 (IQR, 236-378) minutes and 379 (IQR, 312-434) minutes respectively. One hundred forty-nine subjects (83%) achieved good or excellent reperfusion (TICI≥2b), and 16 subjects (9%) failed to achieve any recanalization (TICI=0). The vascular risk factors, pathogenesis of stroke, and operational details were shown in Table 1 .
Among the subjects, 90 of them were treated with tirofiban; comparisons of the demographic and clinical characteristics of subjects treated with tirofiban and without tirofiban are summarized in Table 1 . The age, baseline NIHSS, ASPECTS/ pc-ASPECTS, time from onset to groin puncture and recanalization, location of stroke, vascular risk factors, pathogenesis of stroke, operational details, and TICI scores were not significantly different between groups (P>0.05 each).
Demographic and clinical characteristics of subjects with ACS and PCS are summarized in the Tables I and II in the online-only Data Supplement respectively. Stroke pathogenesis of large artery atherosclerosis was significantly lower in ACS than PCS (58% versus 86%, P<0.001). Compared with 53 of 118 ACS subjects (45%) were treated with tirofiban, 37 of 62 PCS subjects (60%) were treated with tirofiban (P=0.06). And more subjects of PCS were treated with other rescue strategies (ie, intra-arterial thrombolysis and angioplasty; 56% versus 44%, P=0.114).
Intracerebral Hemorrhage
The head CT obtained within 3 days post-treatment showed any ICH in 63 subjects (35%), 19 of them (11%) were sICH, 
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and 9 of them (5%) were fatal ICH. Ten subjects (11%) treated with tirofiban experienced sICH and 9 subjects (10%) not given tirofiban experienced sICH, not a significant difference (P=0.808). The rates of any ICH and fatal ICH were not significantly different between the subjects treated with tirofiban and those not receiving it (37% versus 33% and 7% versus 3% respectively, P>0.1 each, Table 2 ). In the ACS and PCS, the rates of any ICH, sICH, and fatal ICH also were not significantly different between subjects treated with tirofiban and those not receiving it ( Table 2 , P>0.05 each).
Reocclusion
Eleven subjects failed to be assessed by transcranial color Doppler ultrasound because of early death (<24 hours), and 16 subjects (including 4 subjects of early death) did not achieve recanalization. One hundred fifty-seven (including 76 subjects treated with tirofiban and 81 subjects not receiving it) of 180 subjects (87.2%) achieved partial or complete recanalization and had post-treatment transcranial color Doppler, and 21 of them had post-treatment CT angiography. In intention-totreatment analysis, 4 of 90 subjects (4.4%) treated with tirofiban experienced reocclusion, compared with 8 of 90 subjects (8.9%) not treated with tirofiban (odds ratio, 0.50; 95% CI, 0.16-1.60; P=0.370; Table 1 ).
Functional Outcome
At the 3-month follow-up, 43 subjects (24%) had no or minimal symptom (ie, no disability, mRS scored 0-1), 74 subjects (41%) were functionally independent (mRS scored 0-2), and 50 subjects (27%) died. All these outcomes were not significantly different between subjects treated with tirofiban and those not receiving it ( Table 2 , P>0.05 each). In addition, in subjects of ACS and PCS, the distribution of mRS also had no significant difference between subjects treated with tirofiban and those not receiving it ( Table 2 , P>0.05 each). Among all subjects, 161 subjects' long-term functional outcomes were available, including 107 subjects of ACS and 54 subjects of PCS. For those who died, the follow-up periods were recorded from stroke onset to the time that the subject died. The average length of follow-up was 12 (IQR, 3-27) months. At long-term follow-up, 51 subjects (32%) had no disability, 74 subjects (46%) were functionally independent, and 53 subjects (33%) died (Table 3 ). Although the rates of subjects without disability and with functional independence were not significantly different between subjects treated with tirofiban and those not treated, mortality was significantly lower in those treated with tirofiban (23% versus 44%, P=0.005). In ACS subjects, the long-term mortality was also significantly lower in subjects treated with tirofiban (17% versus 37%, P=0.020). In subjects with PCS, although the mortality was lower in subjects treated with tirofiban, there was no significant difference between groups (33% versus 58%, P=0.066).
Multivariate Regression Analysis
Multivariate regression analysis of the effects of tirofiban on ICH and functional outcomes are summarized in Table 4 . Tirofiban was not associated with any ICH, sICH, and fatal ICH (adjusted P>0.05 each) nor was it associated with the 3-month functional outcome and mortality (adjusted P>0.05 each). Intriguingly, although tirofiban was not associated with long-term mortality and the proportion of subjects without disability (adjusted P>0.05 each), it was associated with the proportion of subjects achieving functional independence in the long term (adjusted P=0.033, odds ratio, 4.37; 95% CI, 1.13-16.97).
Discussion
In this study, we found that in AIS patients undergoing ET with second-generation stent-retriever devices, low-dose tirofiban did not increase the risk of any ICH, sICH, fatal ICH, and the 3-month and long-term mortality. And it did not significantly reduce the incidence of early reocclusion. However, tirofiban was associated with a decreased odds of death and an increase in functional independence in the long term.
The results of this study can be considered as externally valid because the median NIHSS scores at admission (20 points), the incidence of sICH (11%), fatal ICH (5%), 3-month mortality (27%), and the incidence of any ICH in ACS patients (46%) were consistent with that of previous studies. 9, 19 Here, we demonstrate that low-dose tirofiban is associated with improved long-term functional independence in AIS patients treated with ET. Data are n (%). ICH indicates intracerebral hemorrhage; mRS, modified Rankin Scale; and sICH, symptomatic intracerebral hemorrhage.
In this study, we found that subjects of PCS were more likely to be treated with tirofiban and other rescue strategies (ie, intra-arterial thrombolysis and angioplasty). This maybe attributable to the different pathogenesis of PCS and ACS. Consistent with previous studies, we found that stroke pathogenesis of large artery atherosclerosis was significantly higher in subjects of PCS than ACS, therefore in situ thrombosis may be more often in PCS. 20 In AIS patients with intracranial atherosclerotic disease, stent-retriever device only can retrieve thrombosis, it cannot solve the underlying atherosclerotic stenosis, and reocclusion is not an infrequent issue, so other rescue strategies (eg, tirofiban) may be required. 6, 20 Contrary to our premise, among patients treated with tirofiban, the rate of failing to achieve any reperfusion (TICI=0) is higher, whereas the rate of good reperfusion (TICI=2b/3) is lower. This may be explained by the fact that the use of tirofiban was at the discretion of the treating interventionists who were prone to use tirofiban in subjects with high possibility of reocclusion after the occluded arteries were partially recanalized during the operation, and not all of them were recanalized or ultimately achieved good reperfusion. 5, 21 This bias likely explains the seemingly paradoxical study results, and randomized controlled trials are needed to further investigate whether tirofiban can improve reperfusion status. Although the possibility of reocclusion may be much higher, the incidence of reocclusion is much lower in subjects treated with tirofiban, this may indicate that low-dose tirofiban is effective in preventing early reocclusion.
Intriguingly, although the rate of successful recanalization was slightly lower in subjects treated with tirofiban, the functional outcome was much better. Invalid recanalization or no reflow may be the underlying reason for this discrepancy. Even if an major arterial occlusion is recanalized after ET, microvascular thrombosis may continue to occur at distal sites. 22 Given their topographical localization to microvessels distributed throughout the ischemic territory, in situ formation of microthrombosis and microembolism during the thrombectomy procedures may contribute to reducing postischemic flow and infarct progression. 22, 23 Studies have determined that glycoprotein IIb/IIIa antagonist (eg, tirofiban) was effective in preventing and treating microthrombosis and accelerating the recovery of AIS. 22, 24 Therefore, we speculate that tirofiban may improve the functional outcome by improving the reperfusion status of microvascular and reducing no reflow phenomenon.
In contrast with a previous study that demonstrated that tirofiban was associated with an increased risk of fatal ICH and poor outcome in AIS patients treated with mechanical thrombectomy, 9 our study found that tirofiban is neither associated with fatal ICH, sICH, and any ICH nor associated with 3-month and long-term mortality, but it is associated with a higher rate of long-term functional independence. These discrepancies may be attributed to several factors. First, in the previous study, more than two thirds of the patients (70%) in the tirofiban group were treated with intravenous alteplase, 9 whereas less than one fourth of patients (24%) in the tirofiban group were treated with intravenous alteplase in this study, which may lower the incidence of sICH in the tirofiban group. In addition, over two thirds of the patients in the tirofiban group were because of large artery atherosclerosis in this study, which may cause differences in the rate of sICH and functional outcome between previously reported study and the *Adjusted for previous stroke, diabetes mellitus, age, baseline NIHSS, pretreatment with antiplatelet or anticoagulation, atrial fibrillation, treatment with additional intra-arterial thrombolysis, treatment with intravenous alteplase, ASPECTS/pc-ASPECTS, and tirofiban.
†Adjusted for previous stroke, diabetes mellitus, age, baseline NIHSS, etiology of stroke, ASPECTS/pc-ASPECTS, location of stroke (posterior or anterior circulation), and thrombolysis in cerebral infarction (TICI) scores, and tirofiban.
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December 2017 present study. 19, 25 More importantly, the method of using tirofiban and its dosing were different in our study. In the present study, a low dose of tirofiban with intra-arterial bolus followed by the intravenous administration was used, which may lower the incidence of sICH and fatal ICH and improve the longterm functional outcome.
Our study has several limitations. First, the dose and duration of tirofiban used in this study was pragmatic. Further studies are needed to determine the optimal tirofiban treatment protocol in AIS patients treated with ET. Furthermore, in this study, the use of tirofiban was at the discretion of the treating interventionist according to the lesions' characteristics and the situation of the procedure, which may have caused bias. In addition, because of the relative low incidence of reocclusion and small simple size, this study is not powered to detect the difference in preventing reocclusion. But the incidence of reocclusion turns out to be much lower in subjects treated with tirofiban, and a much larger study is needed for further investigations. Finally, the underlying mechanisms were not investigated because of the scope of this study.
Summary
In conclusion, in AIS patients treated with ET, a low dose of tirofiban is neither associated with an increase for any ICH, sICH, and fatal ICH nor associated with 3-month and longterm mortality. It seems to lead to a higher rate of long-term functional independence. Further studies are needed to fine tune the optimal treatment protocol that can lead to better efficacy in preventing early reocclusion and improving outcomes. 
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